Karel Odrážka

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Radiotherapy equipment and departments in the European countries: Final results from the ESTRO-HERO survey

Cai Grau, Noémie Defourny, Julian Malicki et al. · Radiotherapy and Oncology · 2014 · 170 citations

Prospective Evaluation of Samarium-153-EDTMP Radionuclide Treatment for Bone Metastases in Patients with Hormone-Refractory Prostate Cancer

Jiří Doležal, J Vizdá, Karel Odrážka · Urologia Internationalis · 2006 · 42 citations

Dose Escalation in Prostate Radiotherapy up to 82 Gy Using Simultaneous Integrated Boost

Martin Doležel, Karel Odrážka, Miloslava Vaculíková et al. · Strahlentherapie und Onkologie · 2010 · 41 citations

Adaptive Radiotherapy, Radiation Medicine, Radiation Therapy +12

Time course of late rectal toxicity after radiation therapy for prostate cancer

Karel Odrážka, Martin Doležel, J Vaňásek et al. · Prostate Cancer and Prostatic Diseases · 2009 · 33 citations

Urology, Radiation Medicine, Surgical Oncology +9